Law report No. GLW-8499 · filed November 6, 2026
Antitrust & CompetitionReported case
Medtronic Hit With Antitrust Suit Over Surgical Stapler Monopoly Claims
Lexington Medical sued Medtronic in Boston federal court, claiming 90% stapler market control through bundling and long-term hospital contracts. Dam damages from the Applied Medical case anchor the evidence.
By Sophie Lindqvist4 min read844 words

Medtronic controls more than 90% of the U.S. laparoscopic surgical stapler market, and a new federal antitrust suit filed Thursday in Boston claims that dominance is illegal. Lexington Medical, a Massachusetts-based seller of laparoscopic universal handle staplers (devices that cut and seal tissue during minimally invasive surgery), brought the 63-page complaint in federal court in Boston. It sues under the Sherman Act and Massachusetts antitrust law, seeking unspecified damages plus an injunction barring Medtronic from "entering into exclusionary and predatory agreements."
The core allegation is blunt. Lexington quotes its own complaint: "This case is about a monopolist that wins through exclusionary conduct what it cannot win on the merits."
What does the complaint allege?
Lexington says its AEON Endoscopic Stapling System outperforms Medtronic's comparable devices. In one head-to-head hospital trial, surgeons rated the AEON stapler "clinically superior" in 89% of cases, according to the filing. Yet the product can't gain traction, Lexington argues, because Medtronic has built a wall around hospital purchasing.
The alleged mechanism has three parts:
- Blocking trials. Lexington claims Medtronic works to stop hospitals from even testing rival staplers.
- Exclusionary bundling. Discounts and rebates reportedly depend on purchases across Medtronic's whole portfolio — staplers, monopolar devices, advanced bipolar devices and other surgical products.
- Long-term contracts. Multi-year agreements lock hospitals into Medtronic's lineup and make switching costly.
Lexington frames the bundling strategy in precise terms. It quotes the complaint: "The bundled discount is not a simple volume discount on staplers. It is a portfolio-wide mechanism to protect Medtronic's stapling share from competition."
The consequence, Lexington argues, is captured in one line: "Hospitals stay locked into Medtronic's portfolio for years, at the cost of higher prices, fewer choices and less innovation."
Where did the evidence come from?
The suit leans heavily on another case. Lexington says its evidence emerged from the federal antitrust action brought by Applied Medical Resources Corp., which Medtronic lost earlier this year. In that case, a jury found Medtronic unlawfully bundled its LigaSure blood-vessel sealing device to protect market share, and the company was ordered to pay $382 million in damages.
Documents from that litigation, cited in Lexington's complaint, are pointed. One purports to show Medtronic instructing its sales force to "communicate violation" if a hospital begins trials of a competitor's product. Another document, Lexington says, describes seeking to "eliminate the competition from getting a window that would allow for a trial."
Lexington also quotes Medtronic's own marketing language. "Medtronic touts that this strategy makes it 'impossible' for a rival to close deals," the complaint states.
What did Medtronic executives say?
Lexington points to statements from Medtronic leadership as evidence of the lock-in strategy. Chief Executive Geoff Martha said in 2025 that the company has "very tight contracts that have been tested over time." A Medtronic regional vice-president, according to the complaint, boasted of customers being "locked down for years to come."
For practitioners, those quotes matter. Contract language and executive statements often serve as direct evidence of exclusionary intent in Sherman Act Section 2 claims (the provision banning monopolization through anticompetitive conduct rather than superior products).
Medtronic representatives did not immediately respond to requests for comment.
Why does this look familiar?
This is not Medtronic's first antitrust fight. The Minnesota-based company lost the Applied Medical Resources case earlier this year, with the jury verdict carrying that $382 million damages figure. Go back further and the pattern continues: in 2010, the now-defunct CareFusion Corporation sued Medtronic, claiming it unlawfully killed competition in the vertebral fracture treatment market. That case was dismissed later the same year.
What does the suit mean for practitioners?
The complaint maps a classic bundling monopolization theory. Think of it as a gym membership: you can't buy access to the weight room unless you pay for the pool, the classes and the lockers, even if a competitor offers a better weight room down the street. Lexington says Medtronic's discounts across staplers, monopolar tools and bipolar devices work the same way — hospitals can't drop the stapler line without losing pricing tiers on everything else.
For antitrust lawyers, the case tests whether evidence from the Applied Medical verdict can carry a second monopolization claim into a new product market. For medical device counsel and hospital procurement teams, it signals fresh scrutiny of portfolio-wide bundle contracts and multi-year exclusivity terms. Any health system negotiating with a dominant supplier should expect plaintiffs' lawyers to read those agreements closely.
Lexington's requested remedy is structural rather than just monetary: an injunction that would bar the specific contract practices at issue, not merely compensate for past harm. That distinction shapes litigation strategy, because injunctions require showing forward-looking harm, not only historical damages.
"Lexington's AEON staplers would win on the merits," the complaint argues. "Medtronic prevents that from happening through anticompetitive conduct."
Medtronic has not yet filed a response. The case is pending in the U.S. District Court for the District of Massachusetts.
via Courthouse News (Source)
More from Sophie Lindqvist
Show full bio
News editor covering people, launches and day-to-day practice in International law and legal practice at Global Law Wire.
333 articles
Also before the court
- Medtronic Ordered to Pay Nearly $382 Million in Antitrust Case
- Medtronic Hit With $382 Million Antitrust Ruling Over Surgical Device Monopoly
- Google Escapes Forced Sale of Chrome and Android in Antitrust Ruling
- Publishers Clear Major Hurdle in Google Ad-Tech Antitrust Case
- Court's Monopoly Finding Against Ticketmaster Opens Path to Reform